|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
GB0206215D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
MXPA05007485A
(es)
|
2003-01-14 |
2006-01-30 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
|
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
JP2004313181A
(ja)
*
|
2003-04-02 |
2004-11-11 |
Canon Inc |
感染症起炎菌検出用プローブ及びプローブセット、ならびに担体及び遺伝子検査方法
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
WO2005012294A1
(en)
|
2003-07-30 |
2005-02-10 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
|
PT1660458E
(pt)
*
|
2003-08-15 |
2012-04-27 |
Novartis Ag |
2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
|
|
US8131475B2
(en)
|
2003-09-03 |
2012-03-06 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
|
EP2543376A1
(en)
|
2004-04-08 |
2013-01-09 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
|
EP1598343A1
(de)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
|
US7521457B2
(en)
*
|
2004-08-20 |
2009-04-21 |
Boehringer Ingelheim International Gmbh |
Pyrimidines as PLK inhibitors
|
|
US7652051B2
(en)
|
2004-08-25 |
2010-01-26 |
Targegen, Inc. |
Heterocyclic compounds and methods of use
|
|
GB0419161D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
BRPI0610876B8
(pt)
|
2005-06-08 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
|
|
TW200740805A
(en)
*
|
2005-07-15 |
2007-11-01 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2007028445A1
(en)
*
|
2005-07-15 |
2007-03-15 |
Glaxo Group Limited |
6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
|
|
GB0517329D0
(en)
*
|
2005-08-25 |
2005-10-05 |
Merck Sharp & Dohme |
Stimulation of neurogenesis
|
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US8133900B2
(en)
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
|
JP5191391B2
(ja)
*
|
2005-11-01 |
2013-05-08 |
ターゲジェン インコーポレーティッド |
キナーゼのビ−アリールメタ−ピリミジン阻害剤
|
|
TW200736232A
(en)
*
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
WO2007085540A1
(en)
*
|
2006-01-27 |
2007-08-02 |
Glaxo Group Limited |
1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
|
|
US7659280B2
(en)
|
2006-02-17 |
2010-02-09 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
|
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
|
PT2450437T
(pt)
|
2006-04-14 |
2017-08-25 |
Cell Signaling Technology Inc |
Defeitos de genes e cinase alk mutante em tumores sólidos humanos
|
|
CA2598893C
(en)
*
|
2006-10-11 |
2012-04-10 |
Astellas Pharma Inc. |
Eml4-alk fusion gene
|
|
EP1914240B1
(en)
|
2006-10-11 |
2009-12-02 |
Astellas Pharma Inc. |
EML4-ALK fusion gene
|
|
ES2555803T3
(es)
|
2006-10-23 |
2016-01-08 |
Cephalon, Inc. |
Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
|
|
EA017405B9
(ru)
|
2006-12-08 |
2014-05-30 |
АйАрЭм ЭлЭлСи |
Соединения и композиции в качестве ингибиторов протеинкиназы
|
|
NZ577197A
(en)
*
|
2006-12-08 |
2011-02-25 |
Irm Llc |
Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
|
|
CN101563327A
(zh)
*
|
2006-12-19 |
2009-10-21 |
健泰科生物技术公司 |
嘧啶类激酶抑制剂
|
|
PE20081636A1
(es)
|
2007-01-26 |
2009-01-10 |
Smithkline Beecham Corp |
Inhibidores de antranilamida para aurora quinasa
|
|
CN101678215B
(zh)
|
2007-04-18 |
2014-10-01 |
辉瑞产品公司 |
用于治疗异常细胞生长的磺酰胺衍生物
|
|
TWI389893B
(zh)
*
|
2007-07-06 |
2013-03-21 |
Astellas Pharma Inc |
二（芳胺基）芳基化合物
|
|
EA201000101A1
(ru)
|
2007-07-16 |
2010-08-30 |
Астразенека Аб |
Производные пиримидина 934
|
|
ES2424977T3
(es)
|
2007-08-08 |
2013-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
|
|
AU2008296479A1
(en)
*
|
2007-08-28 |
2009-03-12 |
Dana Farber Cancer Institute |
Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
|
|
EA017252B1
(ru)
*
|
2007-08-28 |
2012-11-30 |
Айрм Ллк |
Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
|
|
CA2710118A1
(en)
|
2007-12-20 |
2009-07-02 |
Cellzome Limited |
Sulfamides as zap-70 inhibitors
|
|
WO2009105498A1
(en)
*
|
2008-02-19 |
2009-08-27 |
Smithkline Beecham Corporation |
Anilinopyridines as inhibitors of fak
|
|
MX2010010968A
(es)
*
|
2008-04-07 |
2010-10-26 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa de proteina.
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
SG165655A1
(en)
|
2008-04-16 |
2010-11-29 |
Portola Pharm Inc |
2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
|
|
AU2009238590A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
MX353308B
(es)
|
2008-05-21 |
2018-01-08 |
Ariad Pharma Inc |
Derivados fosforosos como inhibidores de cinasa.
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
WO2009153589A1
(en)
*
|
2008-06-17 |
2009-12-23 |
Astrazeneca Ab |
Pyridine compounds
|
|
PE20100087A1
(es)
|
2008-06-25 |
2010-02-08 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
|
US8445505B2
(en)
|
2008-06-25 |
2013-05-21 |
Irm Llc |
Pyrimidine derivatives as kinase inhibitors
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
NZ603525A
(en)
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
JO3067B1
(ar)
*
|
2008-10-27 |
2017-03-15 |
Glaxosmithkline Llc |
بيرميدينات بيرازولو امينو كمثبطات ل fak
|
|
AR074210A1
(es)
|
2008-11-24 |
2010-12-29 |
Boehringer Ingelheim Int |
Derivados de pirimidina como inhibidores de ptk2-quinasa
|
|
TW201024281A
(en)
|
2008-11-24 |
2010-07-01 |
Boehringer Ingelheim Int |
New compounds
|
|
ES2539620T3
(es)
|
2008-12-19 |
2015-07-02 |
Cephalon, Inc. |
Pirrolotriazina como inhibidor de ALK y de JAK2
|
|
BRPI1006942A2
(pt)
|
2009-01-23 |
2016-04-12 |
Rigel Pharmaceuticals Inc |
composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto
|
|
CA2757671A1
(en)
|
2009-04-03 |
2010-10-07 |
Cellzome Ag |
Methods for the identification of kinase interacting molecules and for the purification of kinase proteins
|
|
CA2758614A1
(en)
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
|
EP2440548A1
(en)
*
|
2009-06-10 |
2012-04-18 |
Abbott Laboratories |
2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
|
|
CA2763717A1
(en)
*
|
2009-06-10 |
2010-12-16 |
Cellzome Limited |
Pyrimidine derivatives as zap-70 inhibitors
|
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
|
CA2763720A1
(en)
*
|
2009-06-18 |
2010-12-23 |
Cellzome Limited |
Sulfonamides and sulfamides as zap-70 inhibitors
|
|
EP2443106A1
(en)
*
|
2009-06-18 |
2012-04-25 |
Cellzome Limited |
Heterocyclylaminopyrimidines as kinase inhibitors
|
|
US20120172385A1
(en)
*
|
2009-09-11 |
2012-07-05 |
Richard John Harrison |
Ortho substituted pyrimidine compounds as jak inhibitors
|
|
WO2011140338A1
(en)
*
|
2010-05-05 |
2011-11-10 |
Gatekeeper Pharmaceuticals, Inc. |
Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
|
|
US8927547B2
(en)
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
|
MX336875B
(es)
|
2010-08-10 |
2016-02-04 |
Celgene Avilomics Res Inc |
Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
|
|
EP3323818A1
(en)
|
2010-09-22 |
2018-05-23 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
CA2816219C
(en)
|
2010-11-01 |
2019-10-29 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as syk modulators
|
|
US20130317029A1
(en)
|
2010-11-01 |
2013-11-28 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
EP2635284B1
(en)
|
2010-11-01 |
2019-12-18 |
Celgene CAR LLC |
Heterocyclic compounds and uses thereof
|
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
|
EP2646448B1
(en)
|
2010-11-29 |
2017-08-30 |
OSI Pharmaceuticals, LLC |
Macrocyclic kinase inhibitors
|
|
BR112013015000A2
(pt)
*
|
2010-12-17 |
2016-08-09 |
Novartis Ag |
formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
|
|
US8546443B2
(en)
|
2010-12-21 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Benzylic oxindole pyrimidines
|
|
JP2012153674A
(ja)
|
2011-01-28 |
2012-08-16 |
Astellas Pharma Inc |
ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体
|
|
RS54189B1
(sr)
*
|
2011-02-02 |
2015-12-31 |
Novartis Ag |
Postupci za korišćenje inibitora alk
|
|
US20130324532A1
(en)
|
2011-02-17 |
2013-12-05 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
|
US9174946B2
(en)
|
2011-02-17 |
2015-11-03 |
Cancer Therapeutics Crc Pty Ltd |
Selective FAK inhibitors
|
|
DK2688883T3
(en)
|
2011-03-24 |
2016-09-05 |
Noviga Res Ab |
pyrimidine
|
|
WO2012135641A2
(en)
|
2011-03-30 |
2012-10-04 |
H. Lee Moffitt Cancer Center And Research Institute |
Aurora kinase inhibitors and methods of making and using thereof
|
|
US9139534B2
(en)
|
2011-04-22 |
2015-09-22 |
Signal Pharmaceuticals, Llc |
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
|
|
EP2704572B1
(en)
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
US9364476B2
(en)
|
2011-10-28 |
2016-06-14 |
Celgene Avilomics Research, Inc. |
Methods of treating a Bruton's Tyrosine Kinase disease or disorder
|
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
|
MX363551B
(es)
|
2011-11-23 |
2019-03-27 |
Portola Pharmaceuticals Inc Star |
Compuestos derivados de pirazina como inhibidores de cinasa.
|
|
RS54689B1
(sr)
|
2012-03-06 |
2016-08-31 |
Cephalon, Inc. |
Spojeni biciklični 2,4- diaminopirimidin derivat kao dualni alk i fak inhibitor
|
|
BR112014022790B1
(pt)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
|
|
CA2866852C
(en)
|
2012-03-15 |
2020-12-29 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
KR101582852B1
(ko)
|
2012-05-24 |
2016-01-07 |
서울대학교 산학협력단 |
타우 단백질 매개 신경 퇴행성 질환 치료제
|
|
KR101446742B1
(ko)
*
|
2012-08-10 |
2014-10-01 |
한국화학연구원 |
Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
|
US11230589B2
(en)
|
2012-11-05 |
2022-01-25 |
Foundation Medicine, Inc. |
Fusion molecules and uses thereof
|
|
CN104854101B
(zh)
*
|
2012-11-06 |
2018-05-01 |
上海复尚慧创医药研究有限公司 |
Alk激酶抑制剂
|
|
CN103804299A
(zh)
*
|
2012-11-14 |
2014-05-21 |
韩冰 |
一类具有神经保护作用的化合物及其用途
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
MX2015009952A
(es)
|
2013-02-08 |
2015-10-05 |
Celgene Avilomics Res Inc |
Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
|
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
CA2912806A1
(en)
|
2013-05-29 |
2014-12-04 |
Cephalon, Inc. |
Pyrrolotriazines as alk inhibitors
|
|
BR112015030578A2
(pt)
|
2013-06-18 |
2017-07-25 |
Novartis Ag |
combinações farmacêuticas
|
|
EP3019489A4
(en)
*
|
2013-07-11 |
2016-12-28 |
Betta Pharmaceuticals Co Ltd |
MODULATORS OF TYROSINE KINASE PROTEIN AND METHODS OF USE
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
WO2015038868A1
(en)
*
|
2013-09-13 |
2015-03-19 |
Cephalon, Inc. |
Fused bicyclic 2,4-diaminopyrimidine derivatives
|
|
RU2550346C2
(ru)
|
2013-09-26 |
2015-05-10 |
Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" |
Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
|
|
WO2015058126A1
(en)
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
ES2923942T3
(es)
|
2013-11-06 |
2022-10-03 |
Us Health |
Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
NZ715903A
(en)
|
2014-01-30 |
2017-06-30 |
Signal Pharm Llc |
Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
|
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
|
WO2015164614A1
(en)
*
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
|
EP3179858B1
(en)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Forms and compositions of an erk inhibitor
|
|
WO2016029002A2
(en)
*
|
2014-08-22 |
2016-02-25 |
Clovis Oncology, Inc. |
Growth factor receptor inhibitors
|
|
UA119794C2
(uk)
|
2014-10-21 |
2019-08-12 |
Аріад Фармасьютикалз, Інк. |
Кристалічна форма 5-хлор-n4-[2-(диметилфосфорил)феніл]-n2-{2-метокси-4-[4-(4-метилпіперазин-1-іл)піперидин-1-іл]}піримідин-2,4-діаміну
|
|
CN107108524A
(zh)
|
2014-12-16 |
2017-08-29 |
西格诺药品有限公司 |
2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物
|
|
US9513297B2
(en)
|
2014-12-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
|
|
JP6854762B2
(ja)
|
2014-12-23 |
2021-04-07 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
|
|
PL3242666T3
(pl)
|
2015-01-06 |
2025-02-17 |
Arena Pharmaceuticals, Inc. |
Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
|
|
EP3250557B1
(en)
|
2015-01-29 |
2024-11-20 |
Signal Pharmaceuticals, LLC |
Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
|
|
USRE50776E1
(en)
|
2015-03-27 |
2026-02-03 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
WO2016167511A2
(ko)
*
|
2015-04-14 |
2016-10-20 |
한국화학연구원 |
N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
BR112017027656B1
(pt)
|
2015-06-22 |
2023-12-05 |
Arena Pharmaceuticals, Inc. |
Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
|
|
CN107922287B
(zh)
|
2015-07-24 |
2021-04-09 |
细胞基因公司 |
合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
|
|
AU2016319125B2
(en)
|
2015-09-09 |
2021-04-08 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
CN106699743B
(zh)
*
|
2015-11-05 |
2020-06-12 |
湖北生物医药产业技术研究院有限公司 |
嘧啶类衍生物及其用途
|
|
CN106883213B
(zh)
*
|
2015-12-15 |
2021-04-20 |
合肥中科普瑞昇生物医药科技有限公司 |
一种egfr和alk激酶的双重抑制剂
|
|
US10710993B2
(en)
*
|
2016-06-27 |
2020-07-14 |
Hangzhou REX Pharmaceutical Co., LTD. |
Benzofuran pyrazole amine kinase inhibitor
|
|
CN115043821B
(zh)
|
2016-08-29 |
2024-08-06 |
密歇根大学董事会 |
作为alk抑制剂的氨基嘧啶
|
|
KR101876514B1
(ko)
*
|
2016-11-08 |
2018-07-10 |
한국화학연구원 |
신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물
|
|
MX2019009841A
(es)
|
2017-02-16 |
2020-01-30 |
Arena Pharm Inc |
Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
|
|
KR101923852B1
(ko)
|
2017-02-24 |
2018-11-29 |
재단법인 대구경북첨단의료산업진흥재단 |
혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
|
|
JOP20190281A1
(ar)
*
|
2017-06-13 |
2019-12-02 |
Korea Res Inst Chemical Tech |
مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
|
|
CA3074690A1
(en)
|
2017-09-07 |
2019-03-14 |
Revolution Medicines, Inc. |
Shp2 inhibitor compositions and methods for treating cancer
|
|
KR101992621B1
(ko)
|
2017-12-07 |
2019-09-27 |
주식회사 온코빅스 |
암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
|
|
WO2019117813A1
(en)
*
|
2017-12-15 |
2019-06-20 |
National University Of Singapore |
Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
|
|
JP7085242B2
(ja)
*
|
2017-12-21 |
2022-06-16 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
キナーゼ活性を阻害するためのアリールホスフィンオキシド
|
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
|
CA3102136A1
(en)
|
2018-06-06 |
2019-12-12 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
EP3810132A4
(en)
|
2018-06-25 |
2022-06-22 |
Dana-Farber Cancer Institute, Inc. |
TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
|
|
JP2022508651A
(ja)
|
2018-10-08 |
2022-01-19 |
レヴォリューション・メディスンズ，インコーポレイテッド |
癌を処置するためのｓｈｐ２阻害剤組成物および方法
|
|
WO2020088390A1
(zh)
*
|
2018-10-29 |
2020-05-07 |
江苏先声药业有限公司 |
作为第四代egfr抑制剂的嘧啶吡唑类化合物
|
|
US12522583B2
(en)
|
2018-11-07 |
2026-01-13 |
Dana-Farber Cancer Institute, Inc. |
Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
|
|
EP3877371A4
(en)
|
2018-11-07 |
2022-07-27 |
Dana-Farber Cancer Institute, Inc. |
IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
|
|
EP3876939A4
(en)
|
2018-11-07 |
2022-08-10 |
Dana-Farber Cancer Institute, Inc. |
Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
|
|
US12281126B2
(en)
|
2018-12-28 |
2025-04-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
WO2020147702A1
(en)
*
|
2019-01-17 |
2020-07-23 |
Betta Pharmaceuticals Co., Ltd |
Egfr inhibitors, compositions and methods thereof
|
|
MX2021010323A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos bicíclicos de heterociclilo y usos de este.
|
|
KR102866499B1
(ko)
*
|
2019-03-15 |
2025-10-02 |
더 제너럴 하스피탈 코포레이션 |
Tead 전사인자의 신규한 소분자 저해제
|
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
|
EP3994132A1
(en)
|
2019-07-03 |
2022-05-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
|
KR102168179B1
(ko)
*
|
2019-10-31 |
2020-10-20 |
주식회사 온코빅스 |
암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
|
|
IL322454A
(en)
|
2019-11-04 |
2025-09-01 |
Revolution Medicines Inc |
ras inhibitors
|
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202132316A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
CA3156359A1
(en)
|
2019-11-08 |
2021-05-14 |
Adrian Liam Gill |
Bicyclic heteroaryl compounds and uses thereof
|
|
KR102472103B1
(ko)
*
|
2019-12-03 |
2022-11-29 |
삼진제약주식회사 |
국소 부착 키나아제 저해제로서 신규한 아다만탄 유도체
|
|
WO2021142026A1
(en)
|
2020-01-07 |
2021-07-15 |
Revolution Medicines, Inc. |
Shp2 inhibitor dosing and methods of treating cancer
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
EP4110340A4
(en)
*
|
2020-02-25 |
2024-08-28 |
Dana-Farber Cancer Institute, Inc. |
POTENT AND SELECTIVE ALK DEGRADING AGENTS
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP7849366B2
(ja)
|
2020-12-22 |
2026-04-21 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Ｓｏｓ１阻害剤およびその使用
|
|
WO2022147622A1
(en)
*
|
2021-01-07 |
2022-07-14 |
Ontario Institute For Cancer Research (Oicr) |
Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
|
|
IL307327A
(en)
*
|
2021-04-01 |
2023-11-01 |
Therapex Co Ltd |
Inhibitors of protein kinase with a pyrimidine skeleton, and preparations for treatment containing them
|
|
WO2022208454A1
(en)
*
|
2021-04-02 |
2022-10-06 |
Bridge Biotherapeutics, Inc. |
N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof
|
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ｒａｓ阻害剤及びその使用
|
|
EP4359570A4
(en)
|
2021-06-25 |
2025-04-30 |
Foundation Medicine, Inc. |
METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE IN IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
|
CN119212994A
(zh)
|
2021-12-17 |
2024-12-27 |
建新公司 |
作为shp2抑制剂的吡唑并吡嗪化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR102929746B1
(ko)
|
2023-03-23 |
2026-02-26 |
청주대학교 산학협력단 |
콘크리트 양생용 광발열 단열시트 및 콘크리트 구조물의 조기 시공 방법
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
CN121335887A
(zh)
*
|
2023-06-08 |
2026-01-13 |
希格生科（深圳）有限公司 |
含氮芳环化合物及其医药用途
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
TW202542151A
(zh)
|
2023-12-22 |
2025-11-01 |
美商銳格醫藥有限公司 |
Ｓｏｓ１抑制劑及其用途
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|